ESMO Congress | Conference

Frontline Pembrolizumab Plus Trastuzumab/Chemotherapy Improves PFS in HER2+ Gastric/GEJ Cancer

October 20th 2023

The addition of pembrolizumab to combination of trastuzumab and chemotherapy led to an improvement in progression-free survival vs placebo plus trastuzumab and chemotherapy in the first-line treatment of patients with metastatic HER2-positive gastric or gastroesophageal junction cancer, particularly in those whose tumors had a PD-L1 combined positive score.

Pembrolizumab Plus Adagrasib Demonstrates Preliminary Efficacy in KRAS G12C–Mutated NSCLC

October 20th 2023

Concurrent adagrasib and pembrolizumab generated early signals of efficacy in patients with treatment-naïve, advanced non–small cell lung cancer harboring KRAS G12C mutations, particularly in those who had a PD-L1 tumor proportion score of at least 50%.

Senaparib Maintenance Generates PFS Benefit in Advanced Ovarian Cancer

October 20th 2023

Maintenance therapy consisting of single-agent senaparib reduced the risk of progression or death vs placebo in patients with newly diagnosed advanced ovarian cancer, irrespective of BRCA mutation status.

Durvalumab Plus Chemotherapy Elicits pCR Improvement in Resectable Gastric/GEJ Cancer

October 20th 2023

The addition of durvalumab to 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel produced statistically significant and clinically meaningful improvements in pathological complete response rates vs placebo plus FLOT in patients with resectable gastric cancer or gastroesophageal junction cancer.

Tarlatamab Demonstrates Antitumor Activity With Durable Responses in Previously Treated SCLC

October 20th 2023

Treatment with the bispecific T-cell engager tarlatamab demonstrated antitumor activity and favorable safety outcomes in patients with previously treated small cell lung cancer.

Adjuvant Abemaciclib Plus Endocrine Therapy Sustains iDFS, DRFS Benefit in HR+, HER2– Early Breast Cancer

October 20th 2023

Adjuvant treatment with the combination of abemaciclib and endocrine therapy (ET) maintained a benefit in invasive disease-free survival and distant relapse–free survival compared with ET alone in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer.

ESMO 2023: Experts Preview Anticipated Data Spanning Tumor Types

October 19th 2023

The 2023 ESMO Congress, which is taking place in Madrid, Spain, and will continue to be accessible online via a virtual platform, is gearing up to kick off, and the oncology community is ready to learn more about the latest data across malignancies.

Alpelisib Displays Clinical Benefit in Pediatric PIK3CA-Related Overgrowth Spectrum Disease

September 21st 2022

Alpelisib decreased the need for surgery and led to improvements in performance status and disease-related signs and symptoms in pediatric patients with PIK3CA-related overgrowth spectrum disease who received treatment with the PI3K inhibitor under compassionate use.

Niraparib Maintenance Provides Durable Long-term Remission in High-Risk Advanced Ovarian Cancer

September 15th 2022

Maintenance treatment with niraparib produced a sustained and durable progression-free survival benefit in patients with primary advanced ovarian cancer who responded to first-line platinum-based chemotherapy, spanning biomarker subgroups.

PSA Decline After Lutetium Lu 177 Vipivotide Tetraxetan Treatment Prolongs Survival in PSMA-Positive mCRPC

September 13th 2022

The decline of prostate-specific antigen following treatment with lutetium Lu 177 vipivotide tetraxetan plus standard of care was linked with prolonged radiographic progression-free survival and overall survival in patients with progressive prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.

Lenvatinib/Pembrolizumab Combo Proves Safe, Effective for Metastasized Anaplastic and Poorly Differentiated Thyroid Carcinoma

September 13th 2022

The combination of lenvatinib and pembrolizumab was found to induce high response rates, including long-lasting remissions, and have acceptable safety in patients with metastasized anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma.

PRMT5 Inhibitor Exhibits Efficacy and Tolerability in NHL, Advanced Solid Tumors

September 12th 2022

GSK3326595, a PRMT5 inhibitor, displayed modest efficacy and safety signals that were consistent with those that were previously reported with the agent among patients with advanced solid tumors.

Adagrasib With or Without Cetuximab Elicits Responses in Advanced KRAS G12C–Mutated CRC

September 12th 2022

Adagrasib monotherapy and in combination with cetuximab generated encouraging responses in patients with advanced colorectal cancer harboring KRAS G12C mutations.

Ribociclib Plus Endocrine Therapy Provides Survival Benefit in Advanced HR+/HER2- Breast Cancer With Visceral Metastases

September 12th 2022

Ribociclib plus endocrine therapy elicited statistically significant progression-free survival and overall survival benefits vs placebo plus endocrine therapy in patients with hormone receptor–positive/HER2-negative advanced breast cancer with visceral metastases, including those with liver metastases and multiple metastatic sites.

HRQOL Outcomes in TNBC Are Not Negatively Affected by Pembrolizumab

September 12th 2022

An analysis of patient-reported outcomes from the phase 2 KEYNOTE-522 trial demonstrated that pembrolizumab was not associated with effects on health-related quality of life in patients with triple-negative breast cancer.

Dr. DiSilvestro on 7-Year Follow up of Olaparib Maintenance in Advanced Ovarian Cancer

September 12th 2022

Paul A. DiSilvestro, MD, discusses the 7-year follow up data of maintenance olaparib in advanced ovarian cancer.

Dr. Strickler on the Results of Tucatinib Monotherapy in HER2+ CRC

September 12th 2022

John H. Strickler, MD, discusses the results of tucatinib monotherapy in HER2-positive colorectal cancer.

ctDNA Could Serve as a Prognostic Tool in China for Predicting Outcomes in DLBCL

September 12th 2022

Results from a retrospective analysis presented during the 2022 ESMO Congress indicated that circulating tumor DNA could potentially be leveraged as a prognostic factor and a tumor-specific biomarker for diffuse large B-cell lymphoma in China.

Orelabrutinib Plus R-CHOP Demonstrates Impressive ORR, PFS Rates in Non-GCB DLBCL

September 12th 2022

The combination of orelabrutinib and R-CHOP elicited a favorable overall response rate and progression-free response rate in patients with previously untreated non–germinal center B-cell–like diffuse large B-cell lymphoma (DLBCL) with extranodal disease.

Pembrolizumab/Olaparib Combo Fails to Improve rPFS, OS Vs Novel Hormonal Agents in mCRPC

September 12th 2022

The combination of pembrolizumab and olaparib did not significantly improve radiographic progression-free survival and overall survival compared with novel hormonal agents in patients with molecularly unselected, previously treated metastatic castration-resistant prostate cancer.